Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People

LiuZhou People's Hospital392 enrolled

Overview

Approximately 400 HIV-infected participants aged 1-50 years old will be recruited according to the inclusion and exclusion criteria. Among them, more than 180 participants will be recruited in the immunogenicity and safety study. Each of them will receive 2 doses of the HAV vaccine with a 6-month interval. Blood samples will be drawn before and 1 month after each dose to detect the HAV antibodies to evaluate the immunogenicity of the vaccines. Other people will be recruited in the safety study and receive at least one dose of the HAV vaccine. All the participants will report the adverse events within one month after each dose.

Approximately 400 HIV-infected participants aged 1-50 years old will be recruited in terms of inclusion and exclusion criteria. All participants will receive one dose of the hepatitis A vaccine and have their blood and urine samples collected before and after vaccination for laboratory-related indicator testing. At least 120 HAV-susceptible participants (with anti-HAV antibodies negative before vaccination) and 60 HAV-unsusceptible participants (with anti-HAV antibodies positive before vaccination) aged 18-50 years old, and an unlimited number of HIV-infected children aged 1-17 years old will be included into immunogenicity study, with rest participants included into safety study. Participants in immunogenicity study will receive the second dose of hepatitis A vaccination with a 6-month interval. Blood and urine samples will be collected 1 month, 6months (before second vaccination), and 7 months (1month after second vaccination) after the first vaccination. Participants in safety study will receive second vaccination voluntarily. Adverse events in both immunogenicity and safety study will be collected within 30 days after each dose of vaccination using smartphone mini program or diary cards.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Eligibility

Sex: ALLMin age: 1 YearMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HIV-infected participants aged 1-50 years old * The HIV viral loads of participants in the past 12 months were supposed to be less than 200 copies/ml * Participants or his/her guardian can fully understand and voluntarily sign the informed consent 4. Participants who are willing to participate in the 7-month follow-up 5. Participants who can provide valid legal identification Exclusion Criteria: * Participants who have infected with hepatitis A; * Participants who have been vaccinated with inactivated or live-attenuated hepatitis A vaccine, or hepatitis A and B combined vaccine * Participants who are allergic constitution or severe allergic to vaccines or components in the past (such as acute allergic reaction, angioedema, dyspnea, etc.) * Pregnant women and lactating women * People suffering from uncontrolled epilepsy and other serious neurological diseases (such as transverse myelitis, Guillain-Barré syndrome, demyelinating diseases, etc.) * Participants with fever (axillary temperature ≥37.3℃) during vaccination, or acute exacerbation of chronic diseases, or participants with uncontrolled severe chronic diseases, or suffering from acute diseases * Participants who have received other experimental drugs within 30 days before vaccination with the experimental vaccine * Participants who have received live-attenuated vaccine withins 14 days before vaccination with the experimental vaccine * Participants who have received subunit or inactivated vaccines within 7 days before vaccination with experimental vaccine * According to the investigator's judgment, participants who has any other factors that make him or her unsuitable for vaccination Exclusion Criteria of second vaccination: Participants who meet one of the following events (1) to (4), should not receive the second vaccination, but can continue other study steps according to the investigator's judgment; if participants who meet one of the following events (5) or (6), can still receive the second vaccination according to the investigator's judgment. Participants who meet one of the following events (7) to (10) can postponed the second vaccination within the time window specified in the protocal. 1. Vaccines of the same type other than the experimental vaccine were used during the study; 2. Any serious adverse reaction that is causally related to the experimental vaccination 3. Severe allergic reaction or hypersensitivity reaction after vaccination (including urticaria/rash occurring within 30 minutes after vaccination) 4. Pregnant after the first vaccination (those who had positive result for urine pregnancy test or those who are known to be pregnant) 5. Acute or recently diagnosed chronic disease that occurred after the first vaccination 6. Other reactions (including severe pain, severe swelling, severe limitation of activity, persistent high fever, severe headache, or other systemic or local reactions) are diagonosed by investigator 7. Suffering from acute illness (acute illness refers to moderate or severe illness with or without fever); 8. Axillary temperature ≥37.3℃ during vaccination; 9. Have received subunit vaccine or inactivated vaccine within 7 days, and have received live attenuated vaccine within 14 days 10. According to the investigator's judgment, participants who has any other factors that make him or her unsuitable for vaccination

Outcomes

Primary Outcomes

Seroconversion rate of anti-HAV antibodies 30 days after 2 doses of hepatitis A vaccination among HIV-infected participants with hepatitis A susceptibility

Immunogenicity evaluation

Time frame: 30 days after 2 doses of hepatitis A vaccination

Incidences of adverse reactions within 30 days after each dose of hepatitis A vaccination

safety evaluation

Time frame: 0-30 days after each dose of hepatitis A vaccination

Secondary Outcomes

GMCs of anti-HAV antibodies 30 days after 2 doses of hepatitis A vaccination among HIV-infected participants with hepatitis A susceptibility

Immunogenicity evaluation

Time frame: 30 days after 2 doses of hepatitis A vaccination

GMIs of anti-HAV antibodies 30 days after 2 doses of hepatitis A vaccination among HIV-infected participants with hepatitis A susceptibility

Immunogenicity evaluation

Time frame: 30 days after 2 doses of hepatitis A vaccination

Seropositive rates of anti-HAV antibodies 30 days after 2 doses of hepatitis A vaccination among HIV-infected participants with hepatitis A susceptibility

Immunogenicity evaluation

Time frame: 30 days after 2 doses of hepatitis A vaccination

Seroconversion rates of anti-HAV antibodies 30 days and 6 months after the first dose of hepatitis A vaccination among HIV-infected participants with hepatitis A susceptibility

Immunogenicity evaluation

Time frame: 30 days and 6 months after one dose of hepatitis A vaccination

Seropositive rates of anti-HAV antibodies 30 days and 6 months after 1 dose of hepatitis A vaccination among HIV-infected participants without hepatitis A susceptibility

Immunogenicity evaluation

Time frame: 30 days and 6 months after 1 dose of hepatitis A vaccination

GMCs of anti-HAV antibodies 30 days and 6 months after 1 dose of hepatitis A vaccination among HIV-infected participants without hepatitis A susceptibility

Immunogenicity evaluation

Time frame: 30 days and 6 months after 1 dose of hepatitis A vaccination

GMIs of anti-HAV antibodies 30 days and 6 months after 1 dose of hepatitis A vaccination among HIV-infected participants without hepatitis A susceptibility

Immunogenicity evaluation

Time frame: 30 days and 6 months after 1 dose of hepatitis A vaccination

Incidences of adverse reactions within 7 days after each dose of hepatitis A

safety evaluation

Time frame: 0-7 days after each dose of hepatitis A vaccination

Incidences of adverse events within 7 days and within 30 days after each dose of hepatitis A vaccination

safety evaluation

Time frame: 0-7 days and 0-30 days after each dose of hepatitis A vaccination

Seroconversion rates of anti-HAV antibodies 30 days after 1 does, 30 days and 6 months after 2 doses of hepatitis A vaccination among HIV-infected participants with anti-HAV antibodies seropositivity

Immunogenicity evaluation

Time frame: 30 days after 1 dose, 30 days and 6 months after 2 doses of hepatitis A vaccination

Seropositive rates of anti-HAV antibodies 30 days after 1 does, 30 days and 6 months after 2 doses of hepatitis A vaccination among HIV-infected participants with anti-HAV antibodies seropositivity

Immunogenicity evaluation

Time frame: 30 days after 1 dose, 30 days and 6 months after 2 doses of hepatitis A vaccination

GMC of anti-HAV antibodies 30 days after 1 does, 30 days and 6 months after 2 doses of hepatitis A vaccination among HIV-infected participants with anti-HAV antibodies seropositivity

Immunogenicity evaluation

Time frame: 30 days after 1 dose, 30 days and 6 months after 2 doses of hepatitis A vaccination

GMIs of anti-HAV antibodies 30 days after 1 does, 30 days and 6 months after 2 doses of hepatitis A vaccination among HIV-infected participants with anti-HAV antibodies seropositivity

Immunogenicity evaluation

Time frame: 30 days after 1 dose, 30 days and 6 months after 2 doses of hepatitis A vaccination

The difference in virus loads of HIV before and after vaccination among HIV-infected people

safety evaluation

Time frame: before and within 1 year after vaccination

Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes